Bioventix plc
("Bioventix" or the "Company")
Admission to AIM
The Board of Bioventix plc (AIM: BVXP) is pleased to announce the admission
today of the Company's ordinary shares to trading on the AIM Market of the
London Stock Exchange ("AIM").
finnCap are Nominated Adviser and Broker to the Company. Further information on
the Company, including the Admission document and AIM Rule 26 information, is
detailed on the Company's website, www.bioventix.com.
Peter Harrison, Chief Executive Officer of Bioventix, commented: "I am
delighted Bioventix has joined AIM. This will support the Company's next phase
of growth and provide improved liquidity in the Company's shares for both
existing and new investors. I would like to thank our shareholders for their
support while we were traded on ISDX and look forward to the future with
confidence."
For further information please contact:
Bioventix plc Tel: 01252 728 001
Peter Harrison Chief Executive Officer
finnCap Ltd Tel: 020 7220 0500
Geoff Nash/Simon Hicks Corporate Finance
Steve Norcross Corporate Broking
About Bioventix plc:
Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce a
suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on ISDX under the symbol BVXP.
Translate
